Treatment of Type 1 Diabetes and Other Conditions Using the Gut Microbiome
First Claim
Patent Images
1. A method of treating or preventing impaired glucose homeostasis in a subject comprising the steps of:
- mapping the subject'"'"'s gut microbiome;
comparing the subject'"'"'s gut microbiome results with known mapped gut microbiomes of individuals suffering from particular forms of impaired glucose homeostasis;
determining the particular type of glucose impairment of the subject based on the subject'"'"'s mapped gut microbiome, matching a known mapped gut microbiome of an individual suffering from a particular form of impaired glucose homeostasis;
using one or more islet or beta cell regeneration or replacement therapies; and
administering a T helper lymphocyte 17 (Th17)-inhibitor in an amount that is effective for protection of beta cells from immune-mediated destruction in the subject.
0 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides new methods for treatment of inflammatory and autoimmune diseases including diseases of impaired glucose homeostasis and includes the usage oral usage immunotherapies that are T lymphocyte helper cell 17 (Th17)-inhibitors and usage is based on the patient'"'"'s gut microbiome to determine if they are at risk for targeted organ(s) attack by Th17. The delivery of Th17-inhibitors is delivered preferably orally because Th17 lines the mucosa of the gastrointestinal tract. With the treatment of Type 1 diabetes, both a Th17-inhibitor is used with existing or new islet neogenesis agents presented within.
-
Citations
20 Claims
-
1. A method of treating or preventing impaired glucose homeostasis in a subject comprising the steps of:
-
mapping the subject'"'"'s gut microbiome; comparing the subject'"'"'s gut microbiome results with known mapped gut microbiomes of individuals suffering from particular forms of impaired glucose homeostasis; determining the particular type of glucose impairment of the subject based on the subject'"'"'s mapped gut microbiome, matching a known mapped gut microbiome of an individual suffering from a particular form of impaired glucose homeostasis; using one or more islet or beta cell regeneration or replacement therapies; and administering a T helper lymphocyte 17 (Th17)-inhibitor in an amount that is effective for protection of beta cells from immune-mediated destruction in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of treating or preventing one or more autoimmune diseases or conditions in a subject comprising:
-
mapping the subject'"'"'s gut microbiome; comparing the subject'"'"'s gut microbiome results with known mapped gut microbiomes of other individuals suffering from a particular forms autoimmune disease or condition; determining the particular type of autoimmune disease or condition of the subject based on the subject'"'"'s mapped gut microbiome matching a known mapped gut microbiome of an individual suffering from a particular form of autoimmune disease or condition; and administering a Th17-inhibitor at an amount that is effective for alleviating or preventing symptoms of the autoimmune disease or condition in the subject. - View Dependent Claims (13, 14, 15)
-
-
16. A method of diagnosing and treating one or more diseases that is based on a Th17-initiated inflammatory or autoimmune attack in a subject comprising:
-
mapping the subject'"'"'s gut microbiome; comparing the subject'"'"'s gut microbiome results with known mapped gut microbiomes relating to aberrant gut microbiomes of individual'"'"'s suffering symptoms of Th17-initiated inflammatory or autoimmune attacks; and diagnosing the subject'"'"'s particular type disease based on the subject'"'"'s mapped gut microbiome matching a known mapped gut microbiome of an individual suffering from a particular form of Th17-initiated inflammatory or autoimmune attack. - View Dependent Claims (17, 18, 19, 20)
-
Specification